Skip to main content
Lytix Biopharma AS logo

Lytix Biopharma AS — Investor Relations & Filings

Ticker · LYTIX ISIN · NO0010405780 LEI · 549300NXMIMRSBCDZO71 OL Manufacturing
Open in API
Filings indexed 282 across all filing types
Latest filing 2025-11-11 Regulatory Filings
Country NO Norway
Listing OL LYTIX

About Lytix Biopharma AS

https://www.lytixbiopharma.com/

Lytix Biopharma AS is a clinical-stage immuno-oncology company that develops a proprietary platform of oncolytic molecules for cancer treatment. The company's technology is based on molecules designed to selectively target and lyse cancer cell membranes. This process releases a broad spectrum of tumor antigens, which in turn stimulates a patient's immune system to recognize and attack the cancer, effectively turning immunologically "cold" tumors "hot". Its lead drug candidate, ruxotemitide, is being evaluated in clinical trials as a neoadjuvant treatment for various solid tumors, including melanoma and basal cell carcinoma.

Recent filings

Filing Released Lang Actions
Lytix Biopharma kunngjør lovende interimdata fra NeoLIPA-studien ved Radiumhospitalet
Regulatory Filings Classification · 100% confidence The document is a press release announcing interim clinical trial results (NeoLIPA-studien) for a drug candidate (ruxotemitide). It provides specific clinical data points (pCR rates, patient counts) and quotes from company leadership regarding the implications of these results. It does not fit into financial reporting categories like 10-K or IR, nor is it a report publication announcement (RPA) as it contains the actual data findings rather than just announcing the availability of a report. As it is a general corporate regulatory announcement regarding clinical progress, it falls under the RNS (Regulatory Filings) category.
2025-11-11 Norwegian
New Phase II Study Data from Lytix Biopharma’s Partner Presented at SITC 2025 Further Validate Unique Immune-Activating Mechanism of Ruxotemitide - Attachment: SITC 2025 - Poster - Ruxotemitide (VP-31
Regulatory Filings Classification · 100% confidence The document is a scientific research poster or presentation detailing the results of a Phase 2 clinical trial for an investigational therapy (VP-315) by Verrica Pharmaceuticals. It includes methodology, clinical trial data, results, and conclusions regarding the drug's efficacy and immune response. This type of document is typically categorized as an Investor Presentation or scientific disclosure used to communicate clinical progress to stakeholders, which falls under the 'Investor Presentation' category.
2025-11-10 English
New Phase II Study Data from Lytix Biopharma’s Partner Presented at SITC 2025 Further Validate Unique Immune-Activating Mechanism of Ruxotemitide - Attachment: Lytix SITC Press Release FINAL.pdf
Regulatory Filings Classification · 100% confidence The document is a press release issued by Lytix Biopharma announcing clinical trial results presented at a medical conference (SITC 2025). It does not fit into specific financial reporting categories like 10-K, IR, or ER, nor is it a report publication announcement. As it is a general corporate announcement regarding business/clinical developments, it falls under the 'Regulatory Filings' (RNS) category as the fallback for miscellaneous corporate news.
2025-11-10 English
New Phase II Study Data from Lytix Biopharma’s Partner Presented at SITC 2025 Further Validate Unique Immune-Activating Mechanism of Ruxotemitide
Regulatory Filings Classification · 100% confidence The document is a press release announcing clinical trial results (Phase II study data) for a drug candidate (ruxotemitide). It does not fit into financial reporting categories like 10-K, IR, or ER, nor does it announce a corporate event or governance change. As it is a general regulatory/corporate announcement regarding company operations and clinical progress that does not fall into the other specific categories, it is classified as a Regulatory Filing (RNS).
2025-11-10 English
Financial calendar
Report Publication Announcement Classification · 100% confidence The document is a short notice providing a schedule of upcoming financial reporting dates (a financial calendar). It does not contain financial results or the reports themselves, but rather announces when they will be published. According to the 'Menu vs Meal' rule, an announcement regarding the timing or release of reports is classified as a Report Publication Announcement (RPA).
2025-10-10 English
Finansiell kalender
Report Publication Announcement Classification · 100% confidence The document is a short announcement titled 'Finansiell kalender' (Financial Calendar) for Lytix Biopharma AS, listing the date for the Q3 2025 quarterly report. It does not contain the actual financial report, but rather announces the publication schedule. According to the 'Menu vs Meal' rule, announcements regarding the timing or release of reports are classified as Report Publication Announcements (RPA).
2025-10-10 Norwegian

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.